en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2009
vol. 47
 
Share:
Share:
more
 
 
abstract:
Original paper

Tumour necrosis factor, tumour necrosis factor receptor I and II and acute phase response markers in ankylosing spondylitis patients

Izabela Korczowska-Łącka
,
Hanna Przepiera-Będzak
,
Marek Brzosko
,
Jan.K Łącki
,
Paweł Hrycaj

Reumatologia 2009; 47, 1: 10-14
Online publish date: 2009/03/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Ankylosing spondylitis (AS) is a chronic inflammatory, rheumatological disease affecting primarily the sacroiliac joint and vertebral column. Some clinical and laboratory parameters such as some acute reactive proteins are frequently used to determine the disease activity. Cytokines are soluble proteins that have specific roles in the inflammatory response. This study aimed to evaluate the relation between the level of some acute phase proteins such as C-reactive protein, acid a1-glycoprotein, a1-antichymotrypsin, transferrin, the cytokine tumour necrosis factor-a, and soluble receptors of tumour necrosis factor TNF-RI and TNF-RII, and the clinical findings of patients with AS compared to healthy subjects. In our study we found a correlation between TNF-α levels and AGP and OB as well as a positive correlation between TNF-RI and TNF-RII in our group of patients. We did not find any correlation between BASDAI, BASG-6, BASG-t and acute phase protein. There were also no correlations between TNF-RI and TNF-RII and BASMI and BASDAI.
keywords:

ankylosing spondylitis, tumour necrosis factor a, tumour necrosis factor receptor I, tumour necrosis factor receptor II







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.